Platelets and Anticoagulant Capacity in Patients with Inflammatory Bowel DiseaseLarsen T.B.a · Nielsen J.N.b · Fredholm L.b · Lund E.D.b · Brandslund I.b · Munkholm P.c · Hey H.d
aDepartment of Clinical Biochemistry, Section for Thrombosis and Hemostasis, Aalborg Hospital, Aalborg, bDepartment of Clinical Biochemistry, Vejle County Central Hospital, Vejle, cDepartment of Medical Gastroenterology, University Hospital of Copenhagen, Copenhagen, and dDepartment of Medical Gastroenterology, Vejle County Central Hospital, Vejle, Denmark
Torben Bjerregaard Larsen, MD, PhD
Department of Clinical Biochemistry, Section for Thrombosis and Hemostasis
Aalborg Hospital, Hobrovej 18–22, PO Box 365
DK–9100 Aalborg (Denmark)
Tel. +45 9932 3180, Fax +45 9813 1196, E-Mail firstname.lastname@example.org
Do you have an account?
Patients with inflammatory bowel disease (IBD) are susceptible to thromboembolic complications. Several mechanisms can be responsible, including abnormal regulation of coagulation activity, disturbances of fibrinolysis, inflammatory reactions and thrombocytosis. The aim of this study was to assess hemostatic alterations in these parameters during exacerbation of disease. We studied disease activity in 99 IBD patients receiving anti-inflammatory therapy, in relation to: procoagulant markers, i.e. prothrombin fragment F1 + 2 (F1 + 2), D-dimer and platelet count, anticoagulant markers, i.e. protein C, protein S and antithrombin, and a mediator of inflammation (IL-6). Coagulation activity and platelet count were increased during active disease in IBD patients compared with those in a state of remission. The IL-6 concentrations were positively correlated with disease activity and thrombocytosis in patients with ulcerative colitis, but no association with the anticoagulant capacity could be demonstrated except for a decrease in protein C during high disease activity.
© 2002 S. Karger AG, Basel
Article / Publication Details
Copyright / Drug Dosage / DisclaimerCopyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.